Accelerated Approval Puts Tudriqev Under Continued Scrutiny Ahead of Its Phase 3 Readout

Tudriqev's approval this month came with a condition attached. The FDA granted accelerated approval based on objective response rate, the share of patients whose tumors measurably shrank, rather than on confirmed overall survival benefit. That distinction matters. Full survival data will not arrive until Replimune's Phase 3 confirmatory trial reads out in 2027, and until then the therapy remains under continued regulatory watch.

This is not unusual for the accelerated approval pathway, but the outcomes of that pathway are less predictable than many assume, and that uncertainty carries real implications for anyone tied to the therapy's supply chain.

How Accelerated Approval Actually Works

The FDA created the accelerated approval pathway in 1992 to speed access to treatments for serious conditions, originally in response to the HIV and AIDS crisis. It allows a drug to reach market based on a surrogate endpoint, a measurable signal reasonably likely to predict clinical benefit, while the sponsor completes a confirmatory trial afterward to verify that benefit holds up.

For Tudriqev, that surrogate endpoint is objective response rate. In the IGNYTE trial, roughly a third of evaluable patients achieved a measurable response, with a median duration of response well over a year. That is a meaningful signal, but it is not the same as proof that patients live longer as a result of treatment, which is what the Phase 3 confirmatory trial is designed to establish.

What History Says About Confirmatory Trial Outcomes

The track record for accelerated approvals converting cleanly to full approval is mixed, and the range of outcomes is wider than headlines around any single approval usually suggest.

• A retrospective cohort of 167 accelerated approval indications for anticancer drugs between 1992 and 2022 found 61% were eventually converted to regular approval, while 19% were withdrawn.

• A separate AACR-presented analysis of drugs approved between 2013 and 2017 found that although 63% were converted to regular approval, only 43% had actually demonstrated clinical benefit in confirmatory trials after more than five years of follow-up.

• FDA's own oncology leadership has noted that roughly 15% of oncology drugs granted accelerated approval have ultimately been withdrawn due to failed or incomplete confirmatory trials.

Put together, these numbers show that a meaningful share of accelerated approvals, somewhere between one in five and one in seven by most counts, do not hold up once the confirmatory data comes in.

Why Timing Makes Tudriqev's Case Distinct

Tudriqev's path to approval was already unusually contentious, having been rejected twice before a third resubmission cleared under a compressed review timeline. That history means the therapy arrives on the market with more scrutiny attached than a typical accelerated approval, both from regulators and from the broader medical community.

The Phase 3 confirmatory trial result, expected in 2027, will effectively determine whether this approval is a lasting one. Given the contentious regulatory history and the dissenting advisory committee votes centered on the trial's lack of a placebo-controlled arm, that confirmatory readout is likely to draw close attention when it arrives.

What This Means for Supply Chain Planning

For manufacturers and suppliers connected to Tudriqev's production, whether through viral vector manufacturing inputs, cell culture materials or downstream distribution, the conditional nature of this approval is a factor worth building into planning assumptions.

A few practical considerations follow from the accelerated approval data above.

• Suppliers evaluating long-term capacity commitments tied to a single accelerated approval product should weigh the real possibility of confirmatory trial failure, which historically affects somewhere between one in five and nearly a quarter of oncology accelerated approvals.

• Post-approval commercial demand is likely to build gradually through 2026 and into 2027, rather than immediately, given continued scrutiny and post-approval trial requirements.

• Companies with diversified customer bases across multiple biologics programs are better positioned to absorb the risk of any single accelerated approval product not converting to full approval than those overly concentrated on one product.

What Suppliers Should Watch Next

Tudriqev's accelerated approval opens a genuine commercial opportunity, but it is not a settled one. The therapy's ultimate market durability depends entirely on Phase 3 results still more than a year away, and the historical base rate for confirmatory trial outcomes suggests that outcome is far from certain.

Suppliers and manufacturers connected to this product's supply chain should treat the current approval as the start of a monitoring period rather than a green light for aggressive capacity expansion, watching closely for interim trial updates and any signals from the FDA's post-marketing reporting requirements as 2027 approaches.